Supplier log in
RFP - Supply of immune checkpoint inhibitors for the treatment of locally advanced and metastatic non-small cell lung cancer
Details
|
Tender Closed
|
|
| RFx ID : | 25993408 |
| Tender Name : | RFP - Supply of immune checkpoint inhibitors for the treatment of locally advanced and metastatic non-small cell lung cancer |
| Reference # : | A1593389 |
| Open Date : | Wednesday, 6 July 2022 12:00 PM (Pacific/Auckland UTC+12:00) |
| Close Date : | Wednesday, 31 August 2022 4:00 PM (Pacific/Auckland UTC+12:00) |
| Tender Type : | Request for Proposals (RFP) |
| Tender Coverage : | Sole Agency [?] |
| Categories : |
|
| Regions: |
|
| Exemption Reason : | None |
| Required Pre-qualifications : | None |
| Contact : |
Sam Bright procurement@pharmac.govt.nz . |
| Alternate Physical Delivery Address : | |
| Alternate Physical Fax Number : | |
| Agency Address : | |
REQUEST FOR PROPOSALS – Supply of immune checkpoint inhibitors (ICIs) for the treatment of locally advanced and metastatic non-small cell lung cancer (NSCLC).
Pharmac invites proposals for the supply of ICIs for the treatment of locally advanced and metastatic NSCLC in New Zealand.
This request for proposals (RFP) letter incorporates the following schedules:
· Schedule 1 specifies the pharmaceutical for which Pharmac is requesting proposals and sets out the background to the RFP and the types of proposals sought;
· Schedule 2 describes the process that Pharmac expects to follow in relation to the RFP;
· Schedule 3 sets out information about the estimated size of the market for the pharmaceuticals; and
· Schedule 4 contains the RFP form in which you are to provide details of your proposal.
The other attachments in addition to the RFP letter on this GETS listing are an editable version of the proposal form and Pharmac's standard terms and conditions for supply of pharmaceuticals that would form the basis of the contract for supply.
If you wish to submit a proposal, you must submit it to Pharmac via the Government Electronic Tenders Service (GETS) (www.gets.govt.nz) no later than 4.00 p.m (NZST) on 31 August 2022.
This tender has been awarded. Total spend value $ 140,000,000.
- Merck Sharpe & Dohme (NZ) - Level 3, 123 Carlton Gore Road, Newmarket, Auckland, 1023, NEW ZEALAND
- ROCHE PRODUCTS (NEW ZEALAND) LIMITED - 98, Carlton Gore Road, Newmarket, Auckland, 1023, NEW ZEALAND
Further Award Information:
Te Pātaka Whaioranga (PHARMAC)
Level 9, 40 Mercer Street Wellington
PO Box 10254, Wellington 6143, New Zealand
www.pharmac.govt.nz
Pharmac is pleased to announce the approval of market share agreements progressed through an open RFP for supply of immune checkpoint inhibitors for the treatment of locally advanced and metastatic non-small cell lung cancer.
Pharmac has decided to award Principal Supply Status (“PSS”) to:
• pembrolizumab (brand name Keytruda), supplied by Merck Sharp and Dohme, funded for the treatment of people with advanced NSCLC as first-line treatment.
• atezolizumab (brand name Tecentriq), supplied by Roche, funded for people with advanced NSCLC as second or later line treatment.
Keytruda and Tecentriq have been listed in the Pharmaceutical Schedule from 1 April 2023 for use in community pharmacies and Te Whatu Ora hospitals, with a 5% Alternative Brand Allowance.
Please note:
• The agreements eventuating from this process were provisional on consultation and final approval from the Pharmac Board. The notification date is the ‘approval’ or award date.
• The 7 March 2023 public award notification is available on the Pharmac website here: https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-03-07-decision-to-fund-two-new-treatments-for-people-with-advanced-non-small-cell-lung-cancer/?type=Decision&page=1
• More information about PSS is available here: https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-change-pharmacs-approach-to-competitive-procurement/
• The approximate, estimated, gross annual expenditure for these immune checkpoint inhibitors is $140,000,000
• Pharmac is committed to sustainable and inclusive procurement that delivers for New Zealand and New Zealanders. Broader outcomes were considered in this process.
Award Date: Tuesday, 7 March 2023 (Pacific/Auckland UTC+13:00)
Date RFx was completed/updated: Thursday, 4 May 2023 4:04 PM (Pacific/Auckland UTC+12:00)
